| Product Name | MUC5AC | MUC1 | Purity |
|---|---|---|---|
| Ac5GalNTGc | 98.54% | ||
| Ac5GalNTGc epimer | 98.39% | ||
| Anti-CA6 Antibody (huDS6) | 98.03% | ||
| Anti-CD227/MUC1 Antibody (SPmAb2.1) | |||
| Anti-MUC1/CD227 Antibody (C595 (NCRC48)) | 95.00% | ||
| Anti-MUC16 Antibody (MMUC3333A) | |||
| Anti-MUC16 Antibody (VK8) | |||
| AR20.5 | |||
| Bis(2-methyl-3-furyl)disulfide | 98.37% | ||
| BTH1704 | |||
| Clivatuzumab-MMAE | 98.71% | ||
| CR-1-30-B | 99.92% | ||
| CTM01 | |||
| DS-3939a | 99.15% | ||
| Fexlamose | 99.93% | ||
| Guaimesal | |||
| huCC49 | |||
| huDMB5F3 | |||
| Kaempferol 3-O-gentiobioside | 99.88% | ||
| L-GO-203 TFA | 98.69% | ||
| MA3 aptamer sodium | 95.74% | ||
| MA3 aptamer sodium scrambled negative control | |||
| MUC1, mucin core | 98.84% | ||
| MUC5AC motif peptide | 98.97% | ||
| Nacolomab | |||
| Pemtumomab Antibody | |||
| S2.2 aptamer sodium | 92.06% | ||
| S2.2 aptamer sodium scrambled negative control | |||
| Sacomitatug | 99.90% | ||
| Surzebiclimab | 95.00% | ||
| Tasuldine | |||
| Ubletamig | |||
| Gatipotuzumab | 99.204% | ||
| Clivatuzumab | 99% | ||
| Gefarnate | |||
| House Dust Mite Extract, from D.farinae | |||
| Ensituximab | 99.93% | ||
| Guaifenesin | 99.86% | ||
| Minretumomab | 97.37% | ||
| Sontuzumab | 99.71% | ||
| Sofituzumab | 99.90% |
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号